A 24-month study in Kenya, Uganda and South Africa has found that injectable HIV treatment, Cabotegravir/Rilpivirine, also known in medical terms as CAB LA + RPV LA, administered every two months, is safe, well-tolerated, and preferred by most HIV patients.